ArticleGene therapy2008
Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis.
Article in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Ocular toxicity, distribution, and shedding of intravitreal AAV-eqIL-10 in horses.Molecular therapy. Methods & clinical development · 2024Article
- Case Reports: Chemokine and Cytokine Profiling in Patients with Herpetic Uveitis.International medical case reports journal · 2024Article
- Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases.Journal of neuroinflammation · 2022Review
- Targeting Microglia to Treat Degenerative Eye Diseases.Frontiers in immunology · 2022Review
- Inhibition of experimental autoimmune uveitis by intravitreal AAV-Equine-IL10 gene therapy.PloS one · 2022Article
- Recent advances in the management of non-infectious posterior uveitis.International ophthalmology · 2020Review
- Haematopoietic stem cell gene therapy with IL-1Ra rescues cognitive loss in mucopolysaccharidosis IIIA.EMBO molecular medicine · 2020Article
- The Anti-Inflammatory Effects of Angiogenin in an Endotoxin Induced Uveitis in Rats.International journal of molecular sciences · 2020Article
- AAV-mediated expression of HLA-G1/5 reduces severity of experimental autoimmune uveitis.Scientific reports · 2019Article
- Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model.Frontiers in pharmacology · 2018Article
- The diagnosis and treatment of primary vitreoretinal lymphoma: a review.International journal of retina and vitreous · 2018Review
- Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.Advanced healthcare materials · 2017Review
- The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases.Clinical rheumatology · 2017Review
- Flow cytometric analysis of inflammatory and resident myeloid populations in mouse ocular inflammatory models.Experimental eye research · 2016Article
- Primate neural retina upregulates IL-6 and IL-10 in response to a herpes simplex vector suggesting the presence of a pro-/anti-inflammatory axis.Experimental eye research · 2016Article
- Multimodal analysis of ocular inflammation using the endotoxin-induced uveitis mouse model.Disease models & mechanisms · 2016Article
- Pharmacotherapy for uveitis: current management and emerging therapy.Clinical ophthalmology (Auckland, N.Z.) · 2014Review
- New options for uveitis treatment.International journal of ophthalmology · 2013Review
- Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Impact of IL-1 signalling on experimental uveitis and arthritis.Annals of the rheumatic diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Uveitis is a sight threatening inflammatory disorder that remains a significant cause of visual loss. We investigated lentiviral gene delivery of interleukin 1 receptor antagonist (IL-1ra) or interleukin (IL)-10 to ameliorate murine endotoxin-induced uveitis (EIU). An human immunodeficiency virus-1-based vector containing the mIL-1ra or mIL-10 cDNA demonstrated high expression of biologically active cytokine. Following administration of Lenti.GFP into the anterior chamber, transgene expression was observed in corneal endothelial cells, trabecular meshwork and iris cells. To treat EIU, mice were injected with Lenti.IL-1ra, Lenti.IL-10 or a combination of these. EIU was induced 14 days after vector administration and mice were culled 12 h following disease induction. Lenti.IL-1ra or Lenti.IL-10-treated eyes showed significantly lower mean inflammatory cell counts in the anterior and posterior chambers compared with controls. The aqueous total protein content was also significantly lower in treated eyes, demonstrating better preservation of the blood-ocular barrier. Furthermore, the treated eyes showed less in vivo fluorescein leakage from inner retinal vessels compared with controls. The combination of both IL-1ra and IL-10 had no additive effect. Thus, lentiviral gene delivery of IL-1ra or IL-10 significantly reduces the severity of experimental uveitis, suggesting that lentiviral-mediated expression of immunomodulatory genes in the anterior chamber offers an opportunity to treat uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.